India’s pharmaceutical future: from generics to global leadership
India’s pharmaceutical sector enters 2026 at the threshold of a pivotal five-year phase, focused on building the ecosystem necessary to position itself as a global innovation hub, according to Home Minister Amit Shah, The Pharma Letter’s India correspondent reports.
The journey is part of its long-term ambition to evolve into a $500 billion industry by 2047, even as it navigates immediate challenges such as tariff volatility and shifting global trade dynamics, said the official.
Mr Shah was speaking at a recent ceremony in Gujarat. He emphasized that the pharmaceutical sector is a "strategic national asset," critical to public health, economic strength, and India’s global credibility.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze